Anticoagulation in preterm and term neonates: Why are they special?

Rukhmi Bhat1, Paul Monagle2

  • 1Division of Hematology/Oncology/Transplant, Ann & Robert H. Lurie Children's Hospital of Chicago, Northwestern University Feinberg School of Medicine, Chicago, IL, United States of America.

Thrombosis Research
|January 27, 2020
PubMed

Insights

Neonatal thrombosis requires careful anticoagulation due to infants' unique developmental hemostatic changes. This review covers neonatal thrombosis epidemiology, drug properties, and co-morbidities, highlighting treatment differences.

Area of Science:

  • Pediatric Thrombosis and Hemostasis
  • Neonatal Pharmacology and Therapeutics

Background:

  • Neonates, particularly preterm infants, face the highest risk of thrombotic complications in pediatrics.
  • Anticoagulation is the primary treatment for neonatal thrombosis, but current agents have limitations.
  • Significant developmental hemostatic differences exist between neonates and older children.

Purpose of the Study:

  • To highlight the unique aspects of anticoagulation in neonates compared to other populations.
  • To discuss the epidemiology and risk factors for neonatal thrombosis.
  • To review the pharmacokinetic and pharmacodynamic properties of anticoagulants used in neonates.

Main Methods:

  • Review of current literature on neonatal thrombosis and anticoagulation.
  • Analysis of developmental hemostatic changes in preterm and term infants.
  • Examination of drug properties, co-morbidities, and treatment variability.

Main Results:

  • Neonatal thrombosis is influenced by unique physiological and developmental factors.
  • Existing anticoagulation strategies require careful consideration of neonatal-specific properties.
  • Wide international variability exists in anticoagulant dosing and treatment duration.

Conclusions:

  • Understanding neonatal hemostasis is crucial for effective thrombosis management.
  • Tailored anticoagulation approaches are necessary for the neonatal population.
  • Further research is needed to optimize anticoagulation in neonates.

Related Concept Videos

Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
231
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
205
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
1.5K
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
160
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
186
Venous Thrombosis IV: Nursing Management01:30

Venous Thrombosis IV: Nursing Management

Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...
157